Crimson Biopharm Inc.

Brookline, MA

UEI
ZPMLH22W5Y81
CAGE
9BH28
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Woman Owned Business
  • Asian-Pacific American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
9 Bradford Terrace APT 6, Brookline, MA 02446, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Targeting glioblastoma with CM93, a novel egfr inhibitor with exceptional brain penetration R41CA281586 National Cancer Institute (NIH) $400,000

Quick answers

Is Crimson Biopharm Inc. registered in SAM.gov?

Yes. Crimson Biopharm Inc.'s SAM.gov registration is active through July 18, 2027.

What is Crimson Biopharm Inc.'s most recent federal award?

Crimson Biopharm Inc.'s most recent federal grant award is Targeting glioblastoma with CM93, a novel egfr inhibitor with exceptional brain penetration (R41CA281586), from National Cancer Institute (NIH), on May 15, 2023.

On GovTribe

See Crimson Biopharm Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login